Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

Antimicrobial resistance (AMR) and persistence are associated with an elevated risk of
treatment failure and relapsing infections. They are thus important drivers of increased …

Tumor-resident intracellular microbiota is an emerging tumor component that has been
documented for a variety of cancer types with unclear biological functions. Here, we …

Antimicrobial-resistant ESKAPE (E nterococcus faecium, S taphylococcus aureus, K
lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa, and E …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

The first antibiotic, salvarsan, was deployed in 1910. In just over 100 years antibiotics have
drastically changed modern medicine and extended the average human lifespan by 23 …

Antibiotic resistance caused by antibiotic abuse, especially the emergence of multi-drug
resistant bacteria, poses a serious threat to human health, and makes it imperative to find …

Several interconnected human, animal and environmental habitats can contribute to the
emergence, evolution and spread of antibiotic resistance, and the health of these contiguous …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

The emergence and spread of antibiotic resistance is one of the biggest challenges in public
health. There is an urgent need to discover novel agents against the occurrence of multidrug …